Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Amylin To Celebrate New Year With New Byetta Claim For Use With TZDs

This article was originally published in The Pink Sheet Daily

Executive Summary

Phase III monotherapy data are expected in late 2007, partner Lilly tells “The Pink Sheet” DAILY.
Advertisement

Related Content

Exenatide LAR Phase III Non-Inferiority Data Anticipated In Q4, Amylin Says
Exenatide LAR Phase III Non-Inferiority Data Anticipated In Q4, Amylin Says
Diabetes Drug Spend Could Rise 70 Percent By 2009, Medco Predicts
Diabetes Drug Spend Could Rise 70 Percent By 2009, Medco Predicts
Psylin Neurosciences Will Focus On Development of Psychiatric Drugs
Byetta Shortage Is Bygone Era
Nastech/Amylin’s Exenatide Nasal Spray Deal Could Be Shot In The Arm For Lilly
Amylin Plans Byetta sNDA Submission For Expanded Indication
Amylin Plans Byetta sNDA Submission For Expanded Indication
Byetta Is “Approvable” As Stand-Alone Therapy

Topics

Advertisement
UsernamePublicRestriction

Register

PS063600

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel